PACB
Pacific Biosciences Of Calif
NASDAQ · Life Sciences Tools & Services
$1.82
+0.11 (+6.12%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 169.40M | 160.30M | 208.07M | 209.60M | 233.24M |
| Net Income | -340,793,130 | -290,228,820 | 25.68M | 33.56M | 32.81M |
| EPS | — | — | — | — | — |
| Profit Margin | -201.2% | -191.1% | 12.3% | 16.0% | 14.1% |
| Rev Growth | +5.7% | +5.7% | +0.9% | +11.0% | +6.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 154.14M | 154.14M | 198.94M | 210.64M | 202.72M |
| Total Equity | 120.60M | 120.60M | 248.84M | 247.53M | 237.21M |
| D/E Ratio | 1.28 | 1.28 | 0.80 | 0.85 | 0.85 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -305,892,628 | -274,979,179 | 52.91M | 52.44M | 66.49M |
| Free Cash Flow | — | — | 17.95M | 18.17M | 20.81M |